CSRM617 is a Transcription Factor ONECUT2 Inhibitor for Prostate Cancer
The transcription factor ONECUT2 (OC2) is a master regulator of androgen receptor networks in mCRPC (metastatic castration-resistant prostate cancer ). OC2 acts as a survival factor in mCRPC models. OC2 is a potential drug target in the metastatic phase of aggressive PC. CSRM617, a well-tolerated novel small-molecule inhibitor of...